Charcot-Marie-Tooth Disease (Hereditary Motor-Sensory Neuropathy)

1. Clinical Overview

Answer Card Summary

Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, affecting approximately 1 in 2,500 individuals globally. [1,2] It represents a genetically heterogeneous group of disorders characterized by progressive distal muscle weakness and atrophy, sensory loss, and foot deformities, most notably pes cavus. The clinical hallmark is the "inverted champagne bottle" appearance of the lower limbs due to distal muscle wasting with relative preservation of proximal thigh musculature. [3]

CMT is classified into two principal categories based on nerve conduction studies (NCS): CMT1 (demyelinating forms with median motor nerve conduction velocity less than 38 m/s) and CMT2 (axonal forms with normal or near-normal conduction velocities but reduced amplitudes). [4] CMT1A, caused by duplication of the PMP22 gene on chromosome 17p11.2, accounts for 50-70% of all CMT cases and presents as a demyelinating neuropathy with uniformly slowed conduction velocities. [5,6]

Diagnosis relies on clinical phenotyping, neurophysiological characterization (NCS/EMG), and confirmatory genetic testing. Management is primarily supportive, focusing on physiotherapy, ankle-foot orthoses (AFOs), occupational therapy, and orthopedic surgical interventions for severe foot deformities. [7] Although progressive, most patients with CMT1A remain ambulant throughout life, and life expectancy is typically normal. [8]

Key Clinical Facts

Prevalence: 40 per 100,000 (1 in 2,500), making CMT the most common inherited neuropathy worldwide. [1]
Inheritance: Predominantly autosomal dominant (AD); X-linked (CMTX) and autosomal recessive (AR) forms exist. [2]
"Inverted Champagne Bottle" Sign: Severe distal lower limb atrophy (calves and peroneal muscles) with preserved thigh bulk creates this pathognomonic appearance. [3]
Pes Cavus: High-arched feet with clawed toes result from imbalance between weak intrinsic foot muscles (tibialis anterior, peronei) and relatively preserved extrinsic muscles (gastrocnemius, tibialis posterior). [9]
Areflexia: Ankle jerks are universally absent; knee jerks may be preserved in axonal forms (CMT2) but lost in demyelinating forms (CMT1). [4]
Thickened Nerves: In CMT1, hypertrophic demyelination produces palpably enlarged peripheral nerves (e.g., greater auricular nerve, ulnar nerve at elbow). [10]
Life Expectancy: Generally normal in most CMT subtypes; functional disability varies by genetic subtype and severity. [8]

Clinical Pearls

"Slow and Symmetric": CMT is characteristically insidious in onset (over years to decades) and bilaterally symmetric. Rapid progression (weeks to months) or asymmetry should prompt consideration of acquired inflammatory neuropathies such as CIDP. [11]

"The Clumsy Child": Children with CMT are often labeled as "clumsy" or poor at sports before a formal diagnosis is made. Examination of foot arches and gait pattern (high steppage gait) in any child with chronic motor difficulties is essential. [12]

"Uniform Slowing in CMT1 vs. Patchy Slowing in CIDP": On NCS, CMT1 demonstrates uniform, symmetrical slowing of conduction velocities across all nerve segments, whereas CIDP exhibits multifocal slowing, temporal dispersion, and conduction block. This distinction is critical for differentiating hereditary from acquired demyelinating neuropathies. [11]

"Vincristine Catastrophe": Patients with CMT (particularly CMT1A and CMTX) experience severe, often irreversible neurotoxicity with vincristine chemotherapy. Always screen cancer patients for family history or clinical features of CMT before initiating vinca alkaloid therapy. [13]

"Roussy-Lévy Syndrome": Historical term for CMT1A with prominent postural tremor. This is now recognized as part of the CMT1A spectrum rather than a separate entity. [14]

2. Epidemiology

Incidence and Prevalence

CMT is the most common inherited neuromuscular disorder, with a prevalence of approximately 1 in 2,500 (40 per 100,000). [1,2] This figure is consistent across diverse ethnic populations worldwide. True prevalence may be underestimated due to mild or asymptomatic cases.

Parameter	Value
Global Prevalence	1 in 2,500 (40 per 100,000) [1]
CMT1A Proportion	50-70% of all CMT cases [5]
CMTX Proportion	10-20% of CMT cases [15]
CMT2 Proportion	20-30% of CMT cases [4]

Age and Sex Distribution

Age of Onset: Highly variable. CMT1A typically manifests in the first or second decade of life, though some patients remain asymptomatic until adulthood. CMT2 often has later onset (second to fourth decade). [3,8]
Sex Distribution: Equal incidence in males and females for autosomal forms (CMT1, CMT2). X-linked CMT (CMTX, GJB1 mutations) affects males more severely than heterozygous females. [15]

Geographic and Ethnic Variation

CMT occurs in all ethnic groups without significant geographic clustering. Founder mutations in specific populations (e.g., CMTX in certain regions) may increase local prevalence of particular subtypes. [2]

Exam Detail: Examination Viva: Epidemiology

Q: What is the prevalence of CMT, and which subtype is most common?

Model Answer: CMT has a prevalence of approximately 1 in 2,500, making it the most common inherited peripheral neuropathy. CMT1A, caused by duplication of the PMP22 gene, accounts for 50-70% of all CMT cases. This is followed by CMTX (10-20%) and CMT2 (20-30%). [1,5]

3. Aetiology and Pathophysiology

Genetic Basis

CMT is genetically heterogeneous, with over 100 genes implicated. [16] The most common genetic causes are:

CMT Type	Gene	Locus	Inheritance	Mechanism	Frequency
CMT1A	PMP22 duplication	17p11.2	AD	Myelin instability	50-70% [5]
CMT1B	MPZ (P0)	1q23	AD	Myelin compaction defect	5-10% [6]
CMTX	GJB1 (Connexin-32)	Xq13	X-linked	Gap junction dysfunction	10-20% [15]
CMT2A	MFN2 (Mitofusin-2)	1p36	AD	Mitochondrial fusion defect	Most common CMT2 [17]
CMT4 (AR forms)	Multiple (e.g., GDAP1, SH3TC2)	Various	AR	Varied (myelin/axonal)	Rare overall [16]

Molecular Pathophysiology: The PMP22 Duplication (CMT1A)

The Dosage Effect

Peripheral Myelin Protein 22 (PMP22) is a transmembrane glycoprotein component of compact myelin in peripheral nerves. It constitutes approximately 2-5% of myelin protein content. [5,6] PMP22 expression levels are tightly regulated; both over- and underexpression result in neuropathy.

"Goldilocks Principle of PMP22": [5,6]

PMP22 Gene Copy Number	Condition	Phenotype
1 copy (deletion)	HNPP (Hereditary Neuropathy with Liability to Pressure Palsies)	Recurrent focal pressure palsies
2 copies (normal)	Normal	Stable myelin
3 copies (duplication)	CMT1A	Chronic demyelinating neuropathy
4+ copies (rare)	Severe infantile CMT	Severe early-onset phenotype

The CMT1A duplication arises from unequal crossing over during meiosis, resulting in a 1.4 Mb tandem duplication containing the PMP22 gene. [5] This leads to 1.5-fold overexpression of PMP22 mRNA and protein.

Mechanisms of PMP22-Mediated Demyelination

Myelin Instability: Excess PMP22 disrupts the stoichiometric balance of myelin proteins, leading to unstable myelin compaction. [5]
Protein Aggregation: Overexpressed PMP22 misfolds and aggregates in the endoplasmic reticulum (ER) of Schwann cells, triggering ER stress and the unfolded protein response (UPR). [6]
Schwann Cell Dysfunction: Chronic ER stress impairs Schwann cell function, leading to demyelination and remyelination cycles. [6]
Onion Bulb Formation: Repeated demyelination-remyelination cycles cause proliferation of Schwann cell processes around axons, creating concentric "onion bulb" structures visible on nerve biopsy. [10]

Exam Detail: Viva Deep Dive: PMP22 Biology

Q: Explain the molecular basis of CMT1A and how it differs from HNPP.

Model Answer: CMT1A results from a 1.4 Mb duplication of chromosome 17p11.2 containing the PMP22 gene. This leads to overexpression of PMP22 protein, which disrupts myelin stability and causes ER stress in Schwann cells due to protein misfolding and aggregation. The result is chronic demyelination and remyelination, producing the characteristic hypertrophic neuropathy with onion bulb formation.

In contrast, HNPP is caused by deletion of the same 1.4 Mb region, leading to PMP22 haploinsufficiency. Reduced PMP22 expression makes myelin susceptible to mechanical stress, resulting in focal demyelinating lesions at sites of compression (e.g., peroneal nerve at fibular head, ulnar nerve at elbow). [5,6]

The reciprocal nature of these disorders exemplifies a gene dosage effect: both excess and deficiency of PMP22 cause neuropathy, albeit with different clinical phenotypes.

CMT2 (Axonal Forms): Mitochondrial and Axonal Transport Dysfunction

CMT2 comprises axonal neuropathies with normal or near-normal myelin function. The most common subtype, CMT2A, results from mutations in MFN2 (Mitofusin-2), a mitochondrial outer membrane protein essential for mitochondrial fusion. [17]

Pathophysiology of CMT2A (MFN2 Mutations)

Mitochondrial Fragmentation: Loss of MFN2 function impairs mitochondrial fusion, leading to fragmented, dysfunctional mitochondria. [17]
Axonal Transport Defects: Long peripheral axons depend on mitochondrial trafficking to distal segments. Mitochondrial dysfunction impairs ATP production and disrupts axonal transport. [17]
Distal Axonopathy: Energy failure and transport defects preferentially affect the longest axons (lower limbs > upper limbs), producing length-dependent axonal degeneration. [17]

Other CMT2 genes (e.g., GDAP1, NEFL, HSPB1) similarly disrupt axonal structure, transport, or mitochondrial function. [16]

CMT1 vs. CMT2: Pathophysiological Comparison

Feature	CMT1 (Demyelinating)	CMT2 (Axonal)
Primary Defect	Schwann cell/myelin	Axon (neuronal)
NCS: Conduction Velocity	Uniformly reduced (less than 38 m/s) [4]	Normal or near-normal (> 38 m/s) [4]
NCS: CMAP Amplitude	Mildly reduced	Markedly reduced [4]
Pathology	Onion bulbs, myelin loss [10]	Axonal degeneration, no onion bulbs [10]
Nerve Thickening	Common (palpable nerves) [10]	Absent
Typical Onset	First/second decade [3]	Second/third decade (often later) [3]
Severity	Generally milder [8]	Often more severe [8]

Exam Detail: Viva Deep Dive: Demyelinating vs. Axonal Neuropathy

Q: How do you differentiate demyelinating from axonal neuropathy on nerve conduction studies?

Model Answer: Demyelinating neuropathies (e.g., CMT1) exhibit:

Reduced conduction velocity: Median motor nerve conduction velocity less than 38 m/s in upper limbs. [4]
Prolonged distal latencies and prolonged or absent F-wave latencies.
Preserved or mildly reduced CMAP amplitudes (axons remain relatively intact).
Uniform slowing across all nerve segments in CMT1 (vs. multifocal slowing with conduction block in CIDP). [11]

Axonal neuropathies (e.g., CMT2) exhibit:

Normal or near-normal conduction velocities (> 38 m/s). [4]
Reduced CMAP amplitudes (reflecting axonal loss).
Normal distal latencies and normal F-wave latencies (if axonal loss is not severe).

The pathophysiology differs fundamentally: demyelination slows conduction but preserves axons (initially), whereas axonal degeneration reduces the number of conducting axons but spares myelin function. [4]

4. Clinical Presentation

Classic Phenotype of CMT

The clinical presentation of CMT is distal, symmetric, slowly progressive. The lower limbs are affected earlier and more severely than the upper limbs due to length-dependent degeneration. [3,8]

Motor Features

Lower Limbs

Distal Weakness:
- Foot dorsiflexion weakness (tibialis anterior) causes foot drop and steppage gait (high-stepping to clear toes). [3]
- Ankle eversion weakness (peroneus longus/brevis).
- Toe extension weakness (extensor hallucis longus, extensor digitorum longus).
Distal Muscle Atrophy:
- "Inverted champagne bottle" legs: Wasting of anterior and lateral compartment muscles (tibialis anterior, peronei) and calf muscles (gastrocnemius, soleus) with relative preservation of thigh musculature. [3]
- "Stork legs": Severe distal atrophy creating a thin, spindly appearance.
Foot Deformities:
- Pes cavus (high-arched feet): Results from imbalance between weak dorsiflexors/evertors and relatively preserved plantarflexors/invertors. [9]
- Hammer toes and claw toes: MTP hyperextension with IP flexion due to intrinsic muscle weakness.
- Pes equinovarus: In severe cases, fixed plantarflexion and inversion deformity.

Upper Limbs (Later Manifestation)

Intrinsic Hand Muscle Weakness:
- Weakness of interossei and lumbricals causes difficulty with fine motor tasks (buttoning, writing, handling coins). [3]
- Claw hand deformity: MCP hyperextension with IP flexion (similar mechanism to claw toes).
Thenar and Hypothenar Atrophy: In advanced cases.

Sensory Features

Sensory symptoms are typically milder than motor symptoms and often underreported by patients. [3]

Glove-and-Stocking Sensory Loss:
- Large fiber modalities preferentially affected: vibration sense, proprioception, light touch. [3]
- Small fiber modalities (pain, temperature) relatively preserved in most cases, though some patients experience neuropathic pain or paresthesias.
Sensory Ataxia: Impaired proprioception can cause sensory ataxia and positive Romberg sign.
Complications of Sensory Loss:
- Painless foot ulcers: Pressure points (metatarsal heads) in pes cavus feet with sensory loss.
- Unrecognized injuries: Patients may not notice minor foot trauma.

Reflexes

Ankle jerks: Universally absent or markedly reduced in both CMT1 and CMT2. [4]
Knee jerks: Lost in CMT1 (diffuse demyelination affects all nerve segments); may be preserved in CMT2 (axonal forms with more distal involvement). [4]
Upper limb reflexes: Often preserved until later stages.

Skeletal Deformities

Chronic muscle imbalance drives progressive skeletal changes: [9]

Deformity	Prevalence	Mechanism
Pes cavus	50-90% [9]	Weak tibialis anterior and peronei vs. strong tibialis posterior and peroneus longus
Hammer toes	Common	Intrinsic foot muscle weakness
Kyphoscoliosis	10-20% [9]	Paraspinal muscle weakness and imbalance
Hip dysplasia	Rare	Association with severe early-onset CMT

Additional Features

Palpably Enlarged Nerves: In CMT1 (demyelinating forms), hypertrophic neuropathy may produce palpable thickening of superficial nerves (greater auricular nerve, ulnar nerve at elbow, superficial peroneal nerve). [10]
Tremor: Postural tremor (especially in upper limbs) occurs in some CMT1 patients, historically termed "Roussy-Lévy syndrome." [14]
Hearing Loss: Sensorineural hearing loss in 5% of CMT1A patients. [3]
Vocal Cord Paresis: Rare; may cause hoarseness or stridor.
Diaphragmatic Weakness: Very rare but life-threatening complication in severe CMT4 or some CMT2 variants. [18]

Phenotypic Variability

Significant variability exists even within families carrying the same mutation. Factors influencing severity include:

Genetic modifiers: Variants in other genes may ameliorate or worsen phenotype.
Environmental factors: Activity levels, comorbidities (diabetes exacerbates neuropathy).
Age: Progressive accumulation of disability over decades.

Exam Detail: Examination Viva: Clinical Presentation

Q: Describe the "inverted champagne bottle" sign and explain its pathophysiological basis.

Model Answer: The "inverted champagne bottle" sign refers to severe wasting of the distal lower limb musculature (calves and anterior/lateral compartment muscles) with relative preservation of proximal thigh muscles. This creates a characteristic contour resembling an upside-down champagne bottle. [3]

The pathophysiological basis is length-dependent degeneration: the longest peripheral axons (supplying distal lower limb muscles) are most vulnerable to metabolic stress and degeneration in CMT. Proximal muscles, innervated by shorter axons, are relatively spared until later disease stages. This pattern is typical of both demyelinating (CMT1) and axonal (CMT2) forms but reflects different underlying mechanisms—Schwann cell dysfunction in CMT1 vs. primary axonopathy in CMT2. [3,4]

Q: Why do patients with CMT develop pes cavus?

Model Answer: Pes cavus (high-arched foot) results from chronic muscle imbalance. In CMT, there is weakness of:

Tibialis anterior (ankle dorsiflexor)
Peroneus brevis (ankle evertor)
Intrinsic foot muscles

Meanwhile, extrinsic muscles (tibialis posterior, peroneus longus, gastrocnemius) remain relatively strong. The unopposed action of the peroneus longus plantarflexes the first metatarsal, creating a "forefoot-driven" cavus deformity. Compensatory heel varus develops, and the longitudinal arch heightens. Over time, this becomes structurally fixed. [9]

Pes cavus is both a hallmark of CMT and a contributor to functional disability (ankle instability, pressure ulcers).

Differential Diagnosis of Distal Symmetric Neuropathy

Condition	Key Differentiating Features
CMT	Insidious onset, family history, pes cavus, uniformly slow NCS (CMT1) [3,4]
CIDP	Subacute/chronic (months), acquired, asymmetry, conduction block on NCS, response to immunotherapy [11]
Diabetic Polyneuropathy	Diabetes history, painful neuropathy, autonomic involvement, length-dependent sensory loss [3]
Alcohol-Related Neuropathy	Alcohol history, nutritional deficiency, painful, predominantly sensory [3]
Distal Myopathy	Muscle disease (not nerve), CK elevation, myopathic EMG, normal NCS [3]
Friedreich's Ataxia	Ataxia, cardiomyopathy, diabetes, absent ankle jerks, large fiber sensory loss [3]

5. Investigations

Diagnostic Algorithm

CLINICAL SUSPICION
(Distal weakness, pes cavus, family history)
          ↓
NERVE CONDUCTION STUDIES (NCS) / EMG
          ↓
    ┌─────┴─────┐
  CV less than 38 m/s  CV > 38 m/s
(Demyelinating) (Axonal)
    ↓              ↓
  CMT1          CMT2
    ↓              ↓
GENETIC TESTING
    ↓              ↓
PMP22 dup     MFN2 first
GJB1 (CMTX)   Then panel
MPZ           
Panel if -ve

Nerve Conduction Studies (NCS) and Electromyography (EMG)

NCS is the critical triage test that categorizes CMT into demyelinating vs. axonal forms, guiding subsequent genetic testing. [4]

CMT1 (Demyelinating) NCS Findings

Parameter	Typical Finding
Motor Conduction Velocity	Uniformly slowed: median motor nerve less than 38 m/s [4]
Distal Motor Latency	Prolonged (> 150% of upper limit of normal)
F-Wave Latency	Prolonged or absent
CMAP Amplitude	Mildly reduced or normal (early disease)
Conduction Block	Absent or rare (if present, consider CIDP) [11]
Temporal Dispersion	Minimal (uniform demyelination)
Sensory Nerve Action Potentials (SNAPs)	Reduced amplitude, prolonged latency

Key Distinguishing Feature: Uniform slowing across all nerve segments differentiates hereditary demyelination (CMT1) from acquired demyelination (CIDP, GBS), which shows multifocal slowing, conduction block, and temporal dispersion. [11]

CMT2 (Axonal) NCS Findings

Parameter	Typical Finding
Motor Conduction Velocity	Normal or near-normal (> 38 m/s) [4]
CMAP Amplitude	Reduced (reflects axonal loss) [4]
SNAP Amplitude	Reduced or absent [4]
Distal Latency	Normal or mildly prolonged
F-Wave Latency	Normal or absent (if severe axonal loss)

EMG Findings (Both CMT1 and CMT2)

Chronic denervation: Positive sharp waves, fibrillation potentials in distal muscles.
Chronic reinnervation: Large, polyphasic motor unit potentials (MUPs), reduced recruitment.
Pattern: Distal > proximal; lower limb > upper limb (length-dependent).

Exam Detail: Viva: Nerve Conduction Studies Interpretation

Q: You perform NCS on a 25-year-old with bilateral foot drop and pes cavus. Median motor nerve conduction velocity is 22 m/s, with no conduction block. What is the likely diagnosis, and what genetic test would you order first?

Model Answer: The uniformly slow conduction velocity (less than 38 m/s) without conduction block indicates a hereditary demyelinating neuropathy, most likely CMT1. The absence of conduction block and uniform slowing distinguish this from acquired demyelinating neuropathies like CIDP. [4,11]

Given that CMT1A (PMP22 duplication) accounts for 50-70% of CMT cases, the first genetic test should be PMP22 duplication/deletion analysis by MLPA (multiplex ligation-dependent probe amplification) or chromosomal microarray. [5] If negative, the next step is testing for GJB1 (CMTX, especially in males) and MPZ (CMT1B). [6,15]

Genetic Testing

Genetic testing confirms the diagnosis and enables accurate genetic counseling, prognostication, and family screening. [16]

Stepwise Genetic Testing Strategy

For Demyelinating CMT (Motor CV less than 38 m/s): [5,6,15]

First-line: PMP22 duplication (CMT1A)—accounts for ~70% of demyelinating CMT.
Second-line: GJB1 (CMTX)—especially in males or X-linked pedigree.
Third-line: MPZ (CMT1B).
Fourth-line: Comprehensive CMT gene panel or whole-exome sequencing (WES) if above are negative.

For Axonal CMT (Motor CV > 38 m/s): [16,17]

First-line: MFN2 (CMT2A)—most common CMT2 subtype.
Second-line: CMT2 gene panel (includes MFN2, GDAP1, NEFL, HSPB1, MPZ, others).
Third-line: Whole-exome or whole-genome sequencing if panel negative.

Genetic Testing Technologies

MLPA (Multiplex Ligation-dependent Probe Amplification): Gold standard for detecting PMP22 duplication/deletion.
Sanger Sequencing: For single-gene sequencing (e.g., GJB1, MPZ).
Next-Generation Sequencing (NGS) Panels: Simultaneous sequencing of multiple CMT-associated genes; cost-effective and high-yield.
Whole-Exome Sequencing (WES): For undiagnosed cases after panel testing.

Nerve Biopsy

Nerve biopsy (typically sural nerve) is rarely required in the modern era of comprehensive genetic testing. [10] Historical indications included:

Atypical presentations where genetic testing is negative.
Exclusion of other neuropathies (e.g., vasculitic neuropathy, amyloidosis).

Histopathological Findings in CMT

CMT Type	Pathology
CMT1	"Onion bulbs" (concentric Schwann cell processes), segmental demyelination and remyelination, reduced myelinated fiber density [10]
CMT2	Axonal degeneration, loss of large myelinated fibers, no onion bulbs [10]

Other Investigations

Creatine Kinase (CK): Normal or mildly elevated (helps exclude myopathy).
Vitamin B12, Folate, Thyroid Function: Exclude metabolic neuropathies.
Autoantibodies (e.g., anti-GM1, anti-MAG): If CIDP is suspected.
Lumbar Puncture (CSF Analysis): CSF protein may be mildly elevated in CMT1, but marked elevation (> 1 g/L) suggests CIDP. [11]
MRI Spine: If upper motor neuron signs are present (exclude spinal cord pathology).
Audiometry: Screening for sensorineural hearing loss (especially CMT1A).
ECG/Echocardiography: If cardiac involvement suspected (rare in CMT but can occur in some subtypes).

Exam Detail: Viva: Diagnostic Workup

Q: A 16-year-old presents with progressive foot deformities and difficulty running. His father has similar features. Examination reveals pes cavus, bilateral foot drop, absent ankle jerks, and distal lower limb atrophy. How would you investigate?

Model Answer: This presentation is highly suggestive of CMT given the family history, pes cavus, distal weakness, and areflexia. My investigation strategy would be:

Nerve Conduction Studies (NCS) and EMG: To determine whether the neuropathy is demyelinating (less than 38 m/s) or axonal (> 38 m/s). This guides genetic testing. [4]
Genetic Testing:
- If demyelinating: Test for PMP22 duplication (CMT1A) first. [5]
- If negative: GJB1 (CMTX) and MPZ (CMT1B).
- If axonal: MFN2 (CMT2A) or CMT2 gene panel. [17]
Baseline Assessments:
- CK: To exclude myopathy.
- Audiometry: Screen for hearing loss.
- Foot X-rays: Document pes cavus deformity for future surgical planning.
Genetic Counseling: Discuss inheritance pattern, risk to siblings/future children, and implications of diagnosis. [16]

6. Management

CMT has no curative treatment. Management focuses on:

Preserving mobility and function.
Managing complications (foot deformities, pain).
Genetic counseling and family screening.
Avoiding neurotoxic medications.
Multidisciplinary supportive care. [7,8]

Management Algorithm

                    CMT DIAGNOSIS CONFIRMED
                             ↓
        ┌────────────────────┼────────────────────┐
        ↓                    ↓                    ↓
   REHABILITATION       ORTHOTICS            GENETIC COUNSELING
   - Physiotherapy      - AFOs                - Family screening
   - Occupational       - Insoles             - Reproductive options
     Therapy            - Footwear            - Prognostication
        ↓                    ↓                    ↓
   PAIN MANAGEMENT     SURGICAL             AVOID NEUROTOXINS
   - Neuropathic Rx     - Tendon transfer    - Vincristine
   - Analgesia          - Osteotomies        - Taxanes
                        - Arthrodesis         - High-dose B6
                             ↓
                    MONITOR PROGRESSION
                    - Annual review
                    - CMT Neuropathy Score (CMTNS)

1. Multidisciplinary Rehabilitation

Physiotherapy

Goals: Maintain strength, prevent contractures, optimize gait.

Strengthening Exercises: Focus on ankle dorsiflexors, hip abductors, intrinsic hand muscles. [7]
Stretching: Daily stretching of Achilles tendon to prevent equinus contracture. [7]
Aerobic Exercise: Low-impact exercise (swimming, cycling) is safe and beneficial; does NOT worsen CMT. [7]
Gait Training: Steppage gait modification, use of walking aids (canes, walkers) if needed.

Evidence: Moderate-intensity exercise programs improve strength and fatigue in CMT without accelerating disease progression. [7]

Occupational Therapy

Hand Function: Adaptive devices for fine motor tasks (buttoning aids, wide-grip utensils).
Activities of Daily Living (ADL): Optimize independence (dressing, grooming, cooking).
Workplace Adaptations: Ergonomic assessments, assistive technology.

2. Orthotics and Assistive Devices

Ankle-Foot Orthoses (AFOs)

AFOs are the mainstay of orthotic management for foot drop. [7,9]

AFO Type	Indication	Mechanism
Rigid AFO	Severe foot drop, fixed deformity	Prevents plantarflexion, stabilizes ankle
Hinged AFO	Mild-moderate foot drop	Allows ankle dorsiflexion while preventing plantarflexion
Carbon Fiber AFO	Active patients	Lightweight, dynamic energy return

Evidence: AFOs improve gait efficiency, reduce falls, and decrease energy expenditure in CMT. [9]

Footwear Modifications

Custom insoles: Accommodate pes cavus, redistribute plantar pressure.
High-top boots: Ankle stability, especially in weak ankle invertors/evertors.
Wide toe-box shoes: Accommodate claw toes.

Assistive Devices

Walking sticks/canes: Stability and balance.
Walkers/rollators: For patients with severe weakness.
Wheelchairs: Rarely needed; most CMT1A patients remain ambulant. CMT2A and severe CMT4 subtypes may require wheelchair mobility. [8]

3. Surgical Management

Orthopedic surgery is indicated for severe, rigid foot deformities that do not respond to conservative management and impair function or cause pain. [9]

Timing of Surgery

Pediatric Patients: Delay surgery until skeletal maturity if possible (to avoid recurrence with growth).
Adults: Surgery when deformity is structurally fixed and functionally limiting.

Surgical Procedures for Pes Cavus

Soft Tissue Procedures (for flexible deformities): [9]

Procedure	Indication	Mechanism
Plantar Fascia Release	Flexible pes cavus	Releases tight plantar fascia, lowers arch
Achilles Tendon Lengthening	Equinus contracture	Increases ankle dorsiflexion
Tendon Transfer (e.g., tibialis posterior to dorsum of foot)	Foot drop	Restores dorsiflexion power
Jones Procedure (EHL tendon transfer to 1st metatarsal neck)	Plantarflexed 1st ray	Lifts dropped 1st metatarsal head

Bony Procedures (for rigid deformities): [9]

Procedure	Indication	Mechanism
Dorsiflexion Osteotomy of 1st Metatarsal	Fixed plantarflexed 1st ray	Realigns metatarsal
Calcaneal Osteotomy (Dwyer lateral closing wedge)	Heel varus	Corrects hindfoot alignment
Triple Arthrodesis (talonavicular, subtalar, calcaneocuboid fusion)	Severe rigid deformity	Stabilizes foot, corrects alignment

Evidence: Surgical correction of pes cavus improves function, reduces pain, and prevents ulceration in selected CMT patients. Recurrence rates are higher in pediatric patients. [9]

Hand Surgery

Tendon transfers: For severe intrinsic hand muscle weakness.
Arthrodesis: For unstable joints (rare).

4. Pharmacological Management

No Disease-Modifying Therapy

Currently, there are no approved disease-modifying treatments for CMT. [7,8]

Experimental Therapies (in clinical trials):

PXT3003 (combination of baclofen, naltrexone, sorbitol): Phase 3 trial for CMT1A showed modest benefit on CMT Neuropathy Score in mild patients. [7]
Antisense Oligonucleotides (ASOs) targeting PMP22: Preclinical studies show promise in reducing PMP22 overexpression. [6]
Progesterone Antagonists: PMP22 is upregulated by progesterone; antagonists may reduce PMP22 levels (in development). [6]
Gene Therapy: Early-phase research.

Symptomatic Management

Neuropathic Pain (occurs in 10-40% of CMT patients): [18]

Medication	Dose	Evidence
Gabapentin	300-3600 mg/day	First-line for neuropathic pain [18]
Pregabalin	150-600 mg/day	First-line for neuropathic pain [18]
Amitriptyline	10-75 mg nocte	Second-line (anticholinergic side effects)
Duloxetine	60 mg/day	Second-line

Tremor (if functionally limiting):

Propranolol: 40-240 mg/day for postural tremor.

Fatigue (very common):

No pharmacological treatment proven effective.
Energy conservation strategies, pacing, exercise.

5. Medications to Avoid (Neurotoxic in CMT)

Medication	Risk	Recommendation
Vincristine	Severe, often irreversible neurotoxicity [13]	ABSOLUTELY CONTRAINDICATED in CMT (especially CMT1A, CMTX)
Paclitaxel (Taxanes)	Peripheral neurotoxicity	Avoid or use with extreme caution
Nitrofurantoin	Theoretical risk	Use short courses only if essential; avoid prolonged use
High-dose Vitamin B6 (> 200 mg/day)	Toxic neuropathy	Avoid high-dose supplementation

Critical Clinical Pearl: Always screen cancer patients for CMT (family history, foot deformities, distal weakness) before initiating vinca alkaloid or taxane chemotherapy. Alternative regimens should be used. [13]

6. Genetic Counseling and Family Screening

Inheritance Pattern: Most CMT is autosomal dominant (50% risk to offspring). CMTX is X-linked (affected males, carrier females with variable phenotype). AR forms (CMT4) have 25% recurrence risk for siblings. [16]
Presymptomatic Testing: Offered to at-risk relatives (especially children of affected parents).
Reproductive Options: Preimplantation genetic diagnosis (PGD), prenatal testing available for known familial mutations.
Prognostication: Genotype-phenotype correlation variable; CMT1A generally milder than CMT2A. [8]

7. Monitoring and Follow-Up

Annual Clinic Review: Monitor disease progression, functional status, complications.
CMT Neuropathy Score (CMTNS): Validated outcome measure (motor symptoms, sensory symptoms, strength, sensory testing, NCS). Used in clinical trials and longitudinal monitoring. [8]
Falls Assessment: High risk of falls due to foot drop and proprioceptive loss.
Foot Care: Regular podiatry review, especially if sensory loss (prevent ulcers).
Hearing Assessment: Periodic audiometry (especially CMT1A).
Respiratory Function Tests: If symptoms of respiratory compromise (rare).

Exam Detail: Viva: Management Principles

Q: A 30-year-old woman with CMT1A asks if exercise will worsen her condition. How do you counsel her?

Model Answer: Evidence from controlled trials indicates that moderate-intensity, supervised exercise is safe and beneficial in CMT. It does not accelerate disease progression. [7] In fact, aerobic exercise and strengthening programs improve muscle strength, endurance, and reduce fatigue. I would recommend:

Low-impact aerobic exercise: Swimming, cycling, walking (with AFOs if needed).
Strengthening exercises: Focused on ankle dorsiflexors, hip abductors, and hand intrinsics.
Stretching: Daily Achilles tendon stretching to prevent contractures.
Avoidance of overexertion: Rest when fatigued; pacing strategies.

Physiotherapy-supervised programs are ideal to optimize exercise prescription and avoid injury. [7]

Q: A patient with CMT1A is diagnosed with lymphoma. The oncologist plans vincristine-based chemotherapy. What is your advice?

Model Answer: Vincristine is absolutely contraindicated in CMT, especially CMT1A and CMTX. Patients with CMT experience severe, often irreversible, neurotoxicity with even standard doses of vincristine. [13] I would urgently contact the oncology team to request an alternative chemotherapy regimen that avoids vinca alkaloids (e.g., substitute with an anthracycline or other agent depending on the lymphoma subtype).

If vincristine has already been administered, immediate discontinuation is essential, though recovery may be incomplete. This case highlights the critical importance of screening all patients for CMT (family history, examination for pes cavus, distal weakness) before initiating neurotoxic chemotherapy. [13]

7. Complications

Mobility and Falls

Foot Drop and Steppage Gait: Tripping hazard; increased falls risk. [3]
Ankle Instability: Weak evertors/invertors cause ankle sprains.
Balance Impairment: Proprioceptive loss and distal weakness impair postural stability.

Foot Complications

Pressure Ulcers: Pes cavus creates high plantar pressure at metatarsal heads; sensory loss prevents pain awareness. [9]
Recurrent Ankle Sprains: Due to ankle instability.
Secondary Osteoarthritis: Abnormal biomechanics accelerate joint degeneration.

Pain and Fatigue

Neuropathic Pain: 10-40% of CMT patients experience neuropathic pain (burning, shooting, tingling). [18]
Musculoskeletal Pain: Secondary to gait abnormalities, muscle imbalance.
Chronic Fatigue: Very common; multifactorial (increased energy expenditure, sleep disturbance, chronic pain). [18]

Respiratory Complications (Rare)

Diaphragmatic Weakness: Can occur in severe CMT4 subtypes or some CMT2 variants; presents with dyspnea, orthopnea, respiratory failure. [18]
Sleep Apnea: Associated with vocal cord paresis or central mechanisms (rare).

Scoliosis and Orthopedic Issues

Kyphoscoliosis: 10-20% of CMT patients; may require bracing or surgical correction if severe. [9]
Hip Dysplasia: Rare association with CMT.

Psychosocial Impact

Depression and Anxiety: Chronic disability, progressive nature, uncertainty about future.
Social Isolation: Mobility limitations, difficulty with employment/education.
Body Image Concerns: Visible deformities (pes cavus, claw toes, thin legs).

8. Prognosis and Outcomes

Life Expectancy

Life expectancy is normal in the vast majority of CMT patients, particularly CMT1A. [8] Rare severe subtypes (some CMT4 variants, severe CMT2A) may have reduced lifespan if complicated by respiratory failure.

Functional Prognosis

Prognosis varies by genetic subtype: [8]

CMT Subtype	Typical Severity	Ambulatory Status	Lifespan
CMT1A	Mild to moderate	> 90% remain ambulant [8]	Normal
CMT1B (MPZ)	Variable (mild to severe)	Most ambulant	Normal
CMTX (GJB1)	Males: moderate-severe; Females: mild	Most males ambulant; females usually ambulant	Normal
CMT2A (MFN2)	Moderate to severe	Higher wheelchair risk (20-30% non-ambulant by 40s) [8]	Usually normal
CMT4 (AR forms)	Often severe	Variable; some non-ambulant	Variable (some reduced)

Progression Rate

CMT1A: Very slow progression. Most patients notice worsening over decades, not years. Functional decline accelerates after age 40-50 in some. [8]
CMT2A: Faster progression than CMT1A; greater disability by middle age. [8]

Predictors of Severity

Genotype: CMT2A > CMT1A in severity. [8]
Age of Onset: Earlier onset generally correlates with more severe phenotype.
Baseline Strength: Lower baseline strength predicts faster functional decline.

Quality of Life

Pain and Fatigue: Major determinants of reduced quality of life. [18]
Functional Limitations: Difficulty with ADLs, employment, social participation.
Psychosocial Support: Access to multidisciplinary care, patient support groups (e.g., CMT Association) improves quality of life.

Exam Detail: Viva: Prognosis

Q: A 20-year-old man is newly diagnosed with CMT1A. He asks whether he will end up in a wheelchair. What do you tell him?

Model Answer: The prognosis for CMT1A is generally favorable. Studies show that over 90% of patients with CMT1A remain ambulant throughout their lives. [8] Most patients experience slow progression over decades, and many maintain functional independence with supportive measures such as ankle-foot orthoses (AFOs), physiotherapy, and adaptive strategies.

That said, functional disability accumulates over time, and many patients will require walking aids (canes, walkers) in later life. Wheelchair use is rare in CMT1A but more common in certain axonal subtypes (e.g., CMT2A).

I would emphasize:

Life expectancy is normal. [8]
Supportive therapies (physiotherapy, AFOs, occupational therapy) significantly improve function and quality of life. [7]
Genetic counseling is important for family planning (50% risk to offspring). [16]
Avoidance of neurotoxic drugs (especially vincristine) is critical. [13]

Regular follow-up with a neuromuscular specialist and multidisciplinary team will optimize his long-term outcome. [7]

9. Evidence and Guidelines

Major Guidelines and Consensus Statements

Inherited Neuropathies Consortium (INC) Guidelines: [16]
- Recommendations for genetic testing strategies in CMT.
- Standardized phenotyping and outcome measures.
European Federation of Neurological Societies (EFNS) Guidelines: [7]
- Management of hereditary motor and sensory neuropathies.
Charcot-Marie-Tooth Association (CMTA) Resources: [7]
- Patient-centered guidance, clinical trial updates.

Key Landmark Studies

Inherited Neuropathies Consortium (INC) Natural History Studies: Longitudinal cohort studies defining progression rates, genotype-phenotype correlations, and outcome measures (CMTNS). [8]
PXT3003 Phase 3 Trial (PLEO-CMT): First large-scale therapeutic trial in CMT1A; showed modest improvement in CMTNS in mildly affected patients. [7]
CMT Exercise Studies: Controlled trials demonstrating safety and efficacy of moderate-intensity exercise in CMT. [7]

10. Patient and Layperson Explanation

What is Charcot-Marie-Tooth Disease?

Charcot-Marie-Tooth disease (CMT) is an inherited condition that affects the nerves in your arms and legs. It is the most common inherited nerve disorder, affecting about 1 in 2,500 people.

CMT is caused by changes (mutations) in genes that control how nerves work. These mutations are usually passed down from parents to children. The condition causes the nerves to gradually stop working properly, which leads to weakness and numbness, especially in the feet, ankles, hands, and forearms.

What are the Symptoms?

People with CMT may notice:

Difficulty walking or running (feet may feel weak or "floppy").
High-arched feet (pes cavus) or curled toes.
Frequent tripping or ankle sprains.
Weakness in the hands (difficulty with buttons, zippers, or handwriting).
Numbness or tingling in the feet and hands.

Symptoms usually start in childhood or young adulthood, but some people don't notice problems until later in life.

How is CMT Diagnosed?

Doctors diagnose CMT through:

Physical Examination: Looking for weak muscles, high arches, and reduced reflexes.
Nerve Tests (NCS): Measuring how fast signals travel through your nerves.
Genetic Testing: A blood test to identify the specific gene mutation causing CMT.

What Treatments are Available?

There is currently no cure for CMT, but treatments can help manage symptoms and improve quality of life:

Physiotherapy: Exercises to maintain strength and prevent stiffness.
Ankle-Foot Orthoses (AFOs): Special braces that support weak ankles and prevent foot drop.
Orthopedic Surgery: In some cases, surgery can correct severe foot deformities.
Pain Management: Medications for nerve pain (if present).

Will I End Up in a Wheelchair?

Most people with the most common type of CMT (CMT1A) remain able to walk throughout their lives. However, some people may need walking aids (canes or walkers) as they get older. Wheelchair use is rare.

Can I Pass CMT to My Children?

Yes, CMT is usually inherited. If you have CMT, there is a 50% chance (for most types of CMT) that each of your children will inherit the condition. Genetic counseling can help you understand the risks and options.

Can I Exercise?

Yes! Exercise is safe and beneficial for people with CMT. Moderate-intensity activities like swimming, cycling, and walking (with supportive footwear or braces) can help maintain strength and fitness. Avoid overexertion and listen to your body.

What Should I Avoid?

Certain Medications: Some chemotherapy drugs (especially vincristine) can make CMT much worse. Always tell doctors you have CMT before starting new medications.
High-dose Vitamin B6: Can cause nerve damage.

Where Can I Find Support?

Charcot-Marie-Tooth Association (CMTA): Provides information, support groups, and research updates.
Hereditary Neuropathy Foundation (HNF).
National Organization for Rare Disorders (NORD).

11. Examination Focus: Viva Voce and OSCE Scenarios

Scenario 1: Long Case – CMT1A

Stem: You are asked to examine a 22-year-old man with progressive difficulty walking. He reports frequent tripping and ankle instability since childhood. His father has similar symptoms.

Examination Findings:

Gait: High steppage gait (bilateral foot drop).
Inspection: Pes cavus, hammer toes, distal lower limb muscle wasting ("inverted champagne bottle legs").
Tone: Normal.
Power: MRC grade 3/5 ankle dorsiflexion bilaterally; 4/5 intrinsic hand muscles.
Reflexes: Absent ankle jerks, reduced knee jerks, normal upper limb reflexes.
Sensation: Reduced vibration and proprioception to knees; normal pain and temperature.
Palpation: Thickened ulnar nerves at elbows.

Viva Questions:

Q1: What is your differential diagnosis?

Model Answer: The most likely diagnosis is Charcot-Marie-Tooth disease (CMT), given the family history, pes cavus, distal symmetric weakness, areflexia, and insidious progression. The thickened nerves suggest a demyelinating subtype (CMT1). Differential diagnoses include:

CIDP: But the chronic, symmetric nature and family history favor CMT.
Friedreich's ataxia: But no cerebellar signs or cardiomyopathy reported.
Distal myopathy: But areflexia and sensory loss point to neuropathy, not myopathy.

Q2: What investigations would you perform?

Model Answer:

Nerve Conduction Studies (NCS): To determine if demyelinating (less than 38 m/s) or axonal (> 38 m/s). [4]
Genetic Testing: If demyelinating, test for PMP22 duplication (CMT1A). [5]
Baseline Assessments: CK (exclude myopathy), audiometry (hearing loss screening).
Genetic Counseling: Discuss inheritance, family screening, reproductive options. [16]

Q3: How would you manage this patient?

Model Answer:

Physiotherapy: Strengthening exercises, Achilles stretching, gait training. [7]
Ankle-Foot Orthoses (AFOs): To correct foot drop and improve gait efficiency. [9]
Orthopedic Review: For potential surgical correction of pes cavus if severe. [9]
Genetic Counseling: Discuss 50% risk to offspring; offer presymptomatic testing to siblings. [16]
Medication Avoidance: Counsel to avoid vincristine and other neurotoxic drugs. [13]
Annual Follow-Up: Monitor progression, screen for complications (hearing loss, scoliosis, pain). [8]

Scenario 2: OSCE Station – Genetic Counseling in CMT

Stem: You are a neurology registrar. A 28-year-old woman with CMT1A asks about the risks of passing the condition to her future children. Provide genetic counseling.

Key Points to Cover:

Inheritance Pattern: CMT1A is autosomal dominant. Each child has a 50% chance of inheriting the mutation. [16]
Phenotypic Variability: Even with the same mutation, severity varies. Some family members are mildly affected; others more severely. Progression is generally slow.
Prenatal/Preimplantation Options:
- Preimplantation Genetic Diagnosis (PGD): Embryo testing during IVF to select unaffected embryos.
- Prenatal Testing: Chorionic villus sampling (CVS) or amniocentesis during pregnancy.
- Choice: These are personal decisions; non-directive counseling is essential.
Prognosis: Most people with CMT1A remain ambulant and have normal life expectancy. Supportive therapies (physiotherapy, AFOs) greatly improve function. [7,8]
Family Screening: Siblings and other relatives may benefit from testing if at risk.

Scenario 3: Short Case – Examination of Lower Limbs

Examiner Instruction: "Examine this patient's lower limbs."

Findings: Pes cavus, distal wasting, foot drop, absent ankle jerks.

Presentation: "This patient has bilateral pes cavus with distal lower limb muscle wasting, producing the 'inverted champagne bottle' appearance. There is bilateral foot drop with a high steppage gait. Ankle jerks are absent bilaterally, and vibration sense is reduced to the knees. These findings are consistent with a hereditary sensorimotor neuropathy, most likely Charcot-Marie-Tooth disease. I would like to complete my examination by:

Examining the upper limbs for intrinsic hand muscle wasting and claw hand deformity.
Palpating peripheral nerves (ulnar, greater auricular) for thickening.
Taking a detailed family history.
Arranging nerve conduction studies and genetic testing to confirm the diagnosis and subtype."

12. Deep Dive: Emerging Therapies and Research Directions

Gene-Based Therapies for CMT1A

Antisense Oligonucleotides (ASOs)

ASOs are short, synthetic DNA sequences that bind to PMP22 mRNA, leading to its degradation and reduced PMP22 protein expression. Preclinical studies in CMT1A rodent models show:

Reduction in PMP22 mRNA and protein levels.
Improvement in nerve conduction velocities and muscle strength. [6]

Clinical Development: ASOs targeting PMP22 are in early-phase clinical trials.

Progesterone Receptor Modulators

PMP22 expression is upregulated by progesterone. Progesterone receptor antagonists (e.g., ulipristal acetate) have shown PMP22 reduction in animal models. [6] Clinical trials are underway.

Gene Therapy

Adeno-Associated Viral (AAV) Vectors: Delivery of corrective genes or silencing of mutant genes.
Challenges: Peripheral nerve accessibility, immune responses, long-term expression.

Small Molecule Therapies

PXT3003: Combination of baclofen, naltrexone, and sorbitol. Phase 3 trial (PLEO-CMT) showed modest benefit in CMT Neuropathy Score in mild CMT1A patients. [7]
Neurotrophin Modulators: Agents that promote nerve regeneration and Schwann cell health.

Outcome Measures in CMT Trials

CMT Neuropathy Score (CMTNS): Composite score of symptoms, signs, and electrophysiology. [8]
CMT Pediatric Scale (CMTPedS): For pediatric patients.
Rasch-modified CMT Neuropathy Score (CMTNS-R): Improved sensitivity to change.

13. Red Flag Scenarios and Differential Diagnosis Pitfalls

Red Flag: Rapid Progression

Scenario: A 35-year-old woman with known CMT1A develops rapidly progressive bilateral leg weakness over 3 months.

Differential: CIDP superimposed on CMT. Both can present with demyelinating features on NCS, but CIDP shows:

Asymmetry, conduction block, temporal dispersion. [11]
Elevated CSF protein (> 1 g/L).
Response to immunotherapy (IVIG, steroids, plasmapheresis).

Action: NCS to look for conduction block, LP for CSF protein, trial of IVIG.

Red Flag: Asymmetry

Scenario: A patient with presumed CMT has asymmetric weakness (left leg weaker than right).

Differential:

Acquired neuropathy (CIDP, multifocal motor neuropathy).
Lumbosacral radiculopathy or plexopathy.
Focal nerve lesions (e.g., peroneal nerve palsy at fibular head).

Action: Detailed NCS/EMG, MRI lumbosacral spine, reassess diagnosis.

Red Flag: Upper Motor Neuron Signs

Scenario: A patient with distal weakness and pes cavus has brisk reflexes and upgoing plantars.